Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 18/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7235322 | 1.00 | FDFT1 (0.59) | FDFT1 | |
| SCHEMBL4105355 | 0.93 | FDFT1 (0.59) | FDFT1 | |
| SCHEMBL8924054 | 0.89 | FDFT1 (0.56) | FDFT1 | |
| SCHEMBL7245544 | 0.89 | FDFT1 (0.56) | FDFT1 | |
| SCHEMBL4104065 | 0.88 | FDFT1 (0.51) | FDFT1 | |
| SCHEMBL7235212 | 0.88 | FDFT1 (0.65) | FDFT1 | |
| SCHEMBL4100065 | 0.88 | FDFT1 (0.46) | FDFT1 | |
| SCHEMBL4154674 | 0.87 | FDFT1 (0.56) | FDFT1 | |
| SCHEMBL7236616 | 0.87 | FDFT1 (0.50) | FDFT1 | |
| SCHEMBL4244354 | 0.87 | FDFT1 (0.49) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209510-A1 | Novel Method of Treating Hyperlipidemia | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090118255-A1 | Crp Lowering Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20080132483-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20080113965-A1 | Compound having inhibitory activity against squalene synthase or a salt or prodrug thereof, for example, N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid; myalgia or rhabdomyolysis treatment | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-15 | — | — | US | disclosed |
| US-20080058310-A1 | High-density lipoprotein-cholesterol level elevating agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-06 | — | — | US | disclosed |
| US-20060241096-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | SUGIYAMA YASUO | 2006-10-26 | — | — | US | disclosed |
| US-20060052362-A1 | Skeletal muscle protecting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-09 | — | — | US | disclosed |
| EP-1600166-A1 | SKELETAL MUSCLE PROTECTING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-11-30 | — | — | EP | disclosed |
| US-20040204500-A1 | Preventives/remedies for organ functional disorders and organ dysfunction | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1407782-A1 | PREVENTIVES/REMEDIES FOR ORGAN FUNCTIONAL DISORDERS AND ORGAN DYSFUNCTION | Takeda Chemical Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20040063750-A1 | High-density lipoprotein-cholesterol level elevating agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1332763-A1 | HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL LEVEL ELEVATING AGENT | Takeda Chemical Industries, Ltd. (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-6537987-B1 | This invention relates to certain benzoxazepinones and benzothiazepinones useful as hypocholesterolemic agents, hypotriglyceridemic agents, antiatherosclerosis agents, antifungal agents, anti-Alzheimer's agents or anti-acne | PFIZER INC. | 2003-03-25 | — | — | US | disclosed |
| WO-1997048701-A1 | 4,1-BENZOXAZEPINES OR 4,1-BENZOTHIAZEPINES AND THEIR USE AS SQUALENE SYNTHETASE INHIBITORS | PFIZER INC. (US) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132483-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | FDFT1 1/4885 |
| US-20040204500-A1 | Preventives/remedies for organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | FDFT1 1/4885 |
| US-20080058310-A1 | High-density lipoprotein-cholesterol level elevating agent | SREBF1, SREBF2, HDLBP | FDFT1 10/4885 |
| US-20090118255-A1 | Crp Lowering Agent | SPR, RBP1, HMGCR | FDFT1 7/4885 |
| US-20090209510-A1 | Novel Method of Treating Hyperlipidemia | HMGCR, LIPC, LIPA | FDFT1 12/4885 |
| US-20080113965-A1 | Compound having inhibitory activity against squalene synthase or a salt or prodrug thereof, for example, N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid; myalgia or rhabdomyolysis treatment | SQLE, DHPS, COASY | FDFT1 13/4885 |
| US-20060052362-A1 | Skeletal muscle protecting agent | GYS1, CPT1B, TNNC1 | FDFT1 8/4885 |
| US-20060241096-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | FDFT1 1/4885 |
| US-20040063750-A1 | High-density lipoprotein-cholesterol level elevating agent | SREBF1, SREBF2, HDLBP | FDFT1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.